LivaNova PLC - Ordinary Shares (LIVN)

Record quarterly revenue driven by Essenz upgrades and oxygenator market share gains.

LivaNova (NASDAQ:LIVN) reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses. The company raised its full-year revenue and adjusted EPS outlook while reducing its adjust

LivaNova (LIVN) Q1 2025 Earnings Transcript

LivaNova (LIVN) Q2 2025 Earnings Transcript

LivaNova (LIVN) Q3 2025 Earnings Transcript

LivaNova (LIVN) Q1 2026 Earnings Transcript

LivaNova (LIVN) Q4 2025 Earnings Call Transcript

LivaNova (LIVN) beat Q3 2025 earnings and revenue estimates, raising its full-year guidance on strong performance across its Cardiopulmonary and Neuromodulation segments.

Minneapolis, MN – October 13, 2025 – Inspire Medical Systems (NYSE: INSP) emerged as a standout performer in today's trading session, witnessing its stock price jump by an impressive 3.9% by the closing bell. This significant surge is primarily attributed to the overwhelmingly positive clinical outcomes data presented for its next-generation

LivaNova PLC (NASDAQ:LIVN): An Undervalued Opportunity in Medical Technology

When you look at LIVANOVA PLC (NASDAQ:LIVN), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Discover LIVANOVA PLC, an undervalued stock. NASDAQ:LIVN showcases solid financial health and profitability while maintaining an appealing valuation.

LivaNova gets Buy rating from Goldman Sachs analyst. $65 PT. The company appears poised for consistent revenue growth in its base business.